Janux Therapeutics, Inc. (JANX) NASDAQ
14.84
+0.33(+2.27%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
14.84
+0.33(+2.27%)
Currency In USD
Address
11099 North Torrey Pines Road
San Diego, CA 92037
United States of America (the)
Phone
858 750 4700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
91
First IPO Date
June 11, 2021
| Name | Title | Pay | Year Born |
| David Alan Campbell | President, Chief Executive Officer & Director | 1.13M | 1960 |
| Charles Winter | Chief Technical Officer | 590,400 | 1969 |
| Zachariah Mciver | Chief Medical Officer | 626,400 | 1970 |
| Thomas Diraimondo | Chief Scientific Officer | 630,000 | 1986 |
| Andy Hollman Meyer | Chief Business Officer | 0 | 1984 |
| James Pennington | General Counsel & Corporate Secretary | 0 | N/A |
| Matt Whitmire | Vice President of Finance | 0 | N/A |
| Janeen Doyle | Chief Corporate & Business Development Officer | 0 | N/A |
| Maria Dobek | Principal Accounting Officer & Vice President of Accounting | 0 | 1989 |
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.